S&P 500 Energy Sector SEC Filings — May 26, 2026

26-05-2026

APA Corporation held its 2026 annual meeting on May 21, 2026, where shareholders approved the Third Amendment to the 2016 Omnibus Compensation Plan, increasing authorized shares by 24,160,000 and extending the plan through May 21, 2036. All 10 director nominees were elected, and shareholders ratified Ernst & Young as independent auditor for fiscal 2026. The non-binding advisory vote on executive compensation ('say on pay') passed with 86.0% support, though 38.8 million votes were cast against, indicating notable dissent.

• · The 2016 Omnibus Compensation Plan term was extended through May 21, 2036.
• · All 10 director nominees were elected with the lowest support for Annell R. Bay (97.2% of votes cast excluding broker non-votes) and highest for H. Lamar McKay (99.5%).
• · Ratification of Ernst & Young as independent auditor received 98.5% support (307,082,415 for, 4,653,628 against).
• · The compensation plan amendment received 96.0% support (266,499,823 for, 10,989,332 against).
• · Broker non-votes totaled 34,089,789 shares on all director elections and proposals except the auditor ratification.

26-05-2026

ExxonMobil is soliciting shareholder votes to redomicile the company from Delaware to Texas, aligning its legal structure with its physical headquarters in Spring, Texas. The proposal is presented as maintaining strong shareholder rights and supporting efficient governance and long-term decision-making. The filing includes a LinkedIn post example and voting instructions, with the virtual Annual Shareholder Meeting scheduled for May 27, 2026.

• · The filing is a DEFA14A (definitive additional proxy soliciting materials) filed on May 26, 2026.
• · The proposal to redomicile to Texas is being presented as aligning legal structure with the physical headquarters in Spring, Texas.
• · The virtual Annual Shareholder Meeting is scheduled for May 27, 2026.
• · The filing includes a link to voting instructions and a dial-in for the meeting.

26-05-2026

Hall Chadwick Acquisition Corp (HCACU) reported net income of $1.65M for the three months ended March 31, 2026, and $2.31M since inception (May 22, 2025). The company's cash balance decreased to $463K from $631K at year-end 2025, while cash and investments held in the Trust Account grew to $209.6M. The company remains a pre-business combination SPAC with no operating revenue, and its shareholders' deficit widened to -$5.12M.

• · The company has no operating revenue, with formation, general, and administrative costs of $183K for Q1 2026 and $312K since inception.
• · Interest earned on investments held in Trust Account was $1.84M for Q1 2026 and $2.62M since inception.
• · Basic and diluted net income per share for Class A ordinary shares was $0.08 for Q1 2026 and $0.27 since inception.
• · Basic and diluted net income per share for Class B ordinary shares was $0.21 for Q1 2026 and $0.29 since inception.
• · Total assets were $210.2M as of March 31, 2026, up from $208.6M at December 31, 2025.
• · Total liabilities were $8.32M as of March 31, 2026, down slightly from $8.34M at year-end 2025.
• · Net cash used in operating activities was $173K for Q1 2026 and $364K since inception.
• · The company's shareholders' deficit improved from -$6.78M at December 31, 2025 to -$5.12M at March 31, 2026, primarily due to accumulated profit.

26-05-2026

XOMA Royalty Corporation (XOMAP) is pursuing a merger with Ligand Pharmaceuticals Incorporated, with a Special Meeting of stockholders expected to vote on the Merger Agreement and a Holding Company Reorganization in the third quarter of 2026. Stockholders who do not vote in favor may have dissenters' rights under Nevada law. The merger faces several conditions including regulatory approvals and stockholder approval, and if terminated under certain circumstances, XOMA Royalty would owe a termination fee of $40.0 million. In 2025, XOMA Royalty generated $50.5 million in total cash receipts ($33.6 million from commercial payments and $16.9 million from milestones), and the company has a portfolio of economic rights tied to over 120 commercial and pre-commercial therapeutic candidates, anchored by five commercial-stage assets.

• · HoldCo was formed on May 15, 2026, solely for the purpose of the Holding Company Reorganization and Merger.
• · Completion of the Holding Company Reorganization is a condition to the Merger closing.
• · The Merger is expected to close in the third quarter of 2026, subject to conditions.
• · XOMA Royalty transformed its business model to a royalty aggregator in 2017.
• · Stockholder approval required for both the Merger Agreement and the Holding Company Reorganization.
• · The exchange of Company Shares for cash and CVRs will be a taxable transaction for U.S. federal income tax purposes.
• · If the Merger is not completed, XOMA Royalty will remain an independent public company listed on Nasdaq.
• · Stockholders may exercise dissenters' rights under the Nevada Dissenter's Rights Statutes if they do not vote in favor.